Literature DB >> 29526342

Current thinking about the management of recurrent pleomorphic adenoma of the parotid: a structured review.

A Kanatas1, M W S Ho2, T Mücke3.   

Abstract

Pleomorphic adenoma is the most common tumour of the parotid gland, and can recur after excision. Recurrent pleomorphic adenoma can be a challenge to treat, and has variable outcomes. The aim of this review was to summarise current thinking in its management, which may be helpful to clinical teams and could improve patients' health-related quality of life. We searched several online databases using the key terms pleomorphic adenoma, recurrent pleomorphic adenoma, parotid gland tumours, parotid surgery, radiotherapy and parotid pleomorphic adenoma, and parotid surgery outcomes. Information collected included sample size, recurrence rate, condition of the facial nerve, type of operation, adjuvant treatments associated with recurrence, and clinical outcome. We screened 2301 papers, of which 49 were eligible. There was no consensus among authors about management. There are few if any randomised studies, and so conclusions in most papers were based on coherent arguments. Pleomorphic adenomas of the parotid tend to recur after long intervals, with a propensity towards multifocal disease, and the risk of recurrence (which depends on the initial surgical technique) is higher when the initial operation was done at a young age, after enucleation, and if the initial margins were invaded. Published conclusions suggest that the accepted management varies from observation in selected cases to total parotidectomy with or without postoperative radiotherapy.
Copyright © 2018 The British Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Pleomorphic adenoma; parotid gland; parotid surgery; recurrence

Mesh:

Year:  2018        PMID: 29526342     DOI: 10.1016/j.bjoms.2018.01.021

Source DB:  PubMed          Journal:  Br J Oral Maxillofac Surg        ISSN: 0266-4356            Impact factor:   1.651


  7 in total

Review 1.  Review of surgical techniques and guide for decision making in the treatment of benign parotid tumors.

Authors:  Georgios Psychogios; Christopher Bohr; Jannis Constantinidis; Martin Canis; Vincent Vander Poorten; Jan Plzak; Andreas Knopf; Christian Betz; Orlando Guntinas-Lichius; Johannes Zenk
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-08-04       Impact factor: 2.503

2.  Pattern of facial nerve palsy during parotidectomy: a single-center experience.

Authors:  Abdulwahid M Salih; Hiwa O Baba; Yadgar A Saeed; Aso S Muhialdeen; Fahmi H Kakamad; Shvan H Mohammed; Zuhair D Hammood; Karzan M Salih; Rawezh Q Salih; Dahat A Hussein; Hunar A Hassan
Journal:  J Int Med Res       Date:  2022-07       Impact factor: 1.573

3.  Multifocal recurrence of pleomorphic adenoma of the lacrimal gland.

Authors:  Jiawei Zhao; Alexandra M Papp; Michelle D Williams; J Matthew Debnam; Bita Esmaeli
Journal:  Am J Ophthalmol Case Rep       Date:  2022-05-27

4.  Salivary Gland Pleomorphic Adenomas Presenting With Extremely Varied Clinical Courses. A Single Institution Case-Control Study.

Authors:  Krzysztof Piwowarczyk; Ewelina Bartkowiak; Paweł Kosikowski; Jadzia Tin-Tsen Chou; Małgorzata Wierzbicka
Journal:  Front Oncol       Date:  2021-01-08       Impact factor: 6.244

5.  Long-term Follow-up after Extracapsular Dissection of Parotid Pleomorphic Adenomas - A Retrospective Study.

Authors:  Walter Colangeli; Valerio Facchini; Aleksandr Kapitonov; Fabrizio Bozza; Roberto Becelli
Journal:  Ann Maxillofac Surg       Date:  2022-02-01

6.  Novel Technique for the Surgical Management of Pleomorphic Adenoma of the Upper Lip.

Authors:  Dyna Albert; Senthil Murugan Pandurangan; Purva Kulkarni; Santhosh P Kumar; Murugesan Krishnan; Twinkle Francis
Journal:  Cureus       Date:  2022-07-24

7.  Deep Learning for Differentiating Benign From Malignant Parotid Lesions on MR Images.

Authors:  Xianwu Xia; Bin Feng; Jiazhou Wang; Qianjin Hua; Yide Yang; Liang Sheng; Yonghua Mou; Weigang Hu
Journal:  Front Oncol       Date:  2021-06-23       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.